Extract from the Register of European Patents

EP Citations: EP3326616

Cited inSearch
Type:Patent literature
Publication No.:US5023087  [XI]
 (YAU-YOUNG ANNIE [US]) [X] 1-9,14 * example 8; claim 1 * [I] 10-13,15;
Type:Patent literature
Publication No.:US2010093873  [XI]
 (GOLDFISCHER SIDNEY L [US]) [X] 1-9,13,14 * paragraphs [0006] , [0015]; claim 1 * [I] 10-12,15;
Type:Patent literature
Publication No.:US2005233970  [A]
 (GARNICK MARC B [US]) [A] 1-15 * the whole document *
Type:Non-patent literature
Publication information:[X]  - MAYER L D ET AL, "INTRAVENOUS PRETREATMENT WITH EMPTY PH GRADIENT LIPOSOMES ALTERS THE PHARMACOKINETICS AND TOXICITY OF DOXORUBICIN THROUGH IN VIVO ACTIVE DRUG ENCAPSULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (19990101), vol. 88, no. 1, doi:10.1021/JS980202H, ISSN 0022-3549, pages 96 - 102, XP000789043 [X] 1-15 * Abstract; page 97, left column paragraph 2 *
DOI: http://dx.doi.org/10.1021/js980202h
Type:Non-patent literature
Publication information:[A]  - T. NOUSIAINEN ET AL, "QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma", JOURNAL OF INTERNAL MEDICINE, (19990401), vol. 245, no. 4, doi:10.1046/j.1365-2796.1999.00480.x, ISSN 0954-6820, pages 359 - 364, XP055148526 [A] 1-15 * abstract *
DOI: http://dx.doi.org/10.1046/j.1365-2796.1999.00480.x
Cited inExamination
Type:Patent literature
Publication No.:EP2133074  
Cited inby applicant
Type:Patent literature
Publication No.:US2010004549  
Type:Patent literature
Publication No.:US2008255464  
Type:Patent literature
Publication No.:US2007048284  
Type:Patent literature
Publication No.:US2010120890  
Type:Patent literature
Publication No.:US5679864  
Type:Non-patent literature
Publication information:   - ANDERSON CL.; DELISLE BP; ANSON BD, "Most LQT2 Mutations Reduce Kvl 1.1 (hERG) Current by a class2 (Trafficking Deficient) Mechanism", Circulation, (20060000), vol. 113, pages 365 - 373
Type:Non-patent literature
Publication information:   - COMPTONSJ; LUX RL; RAMSEY MR et al., "Genetically defined therapy of inherited long QT syndrome", Correction of abnormal repolarization by potassium, (19960000), vol. 94, pages 1018 - 1022
Type:Non-patent literature
Publication information:   - DJEDDI D; KONGOLO G; LEFAIX C; MOUNARD J; LEKE A, "Effect of domperidone on QT interval in neonates", J Pediatrics, (20080000), vol. 153, no. 5, doi:doi:10.1016/j.jpeds.2008.05.013, pages 596 - 598, XP025779944
DOI: http://dx.doi.org/10.1016/j.jpeds.2008.05.013
Type:Non-patent literature
Publication information:   - DUCROQ J.; PRINTEMPS R; LE GRAND M., "Additive effects ziprasidone and D,L-sotalol on the action potential in rabbit purkinje fibers and on the hERG potassium current", J.Pharmacol. Toxicol Methods, (20050000), vol. 52, doi:doi:10.1016/j.vascn.2005.04.001, pages 115 - 122, XP004985398
DOI: http://dx.doi.org/10.1016/j.vascn.2005.04.001
Type:Non-patent literature
Publication information:   - ETHERIDGE SP; COMPTON SJ; TRISTANI-FIROUZI M; MASON JW, "A new oral therapy for long QT syndrome: long term oral potassium improves repolarization in patients with hERG mutations", J AM Coll Cardiol, (20030000), vol. 42, pages 1777 - 1782
Type:Non-patent literature
Publication information:   - FAUCHIER L; BABUTY D; PORET P; AUTRET ML; COSNAY P; FAUCHIER JP, "Effect of Verapamil on QT interval dynamicity", AM J Cardiol., (19990000), vol. 83, no. 5, pages 807 - 808
Type:Non-patent literature
Publication information:   - FOWLER NO; MCCALL D; CHOU TC; HILMES JC; HANENSON IB, "Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs", Am J Cardiol, (19760000), vol. 37, no. 2, doi:doi:10.1016/0002-9149(76)90316-7, pages 223 - 230, XP026333604
DOI: http://dx.doi.org/10.1016/0002-9149(76)90316-7
Type:Non-patent literature
Publication information:   - JERVELL A; LANG-NIELSON F, "Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death", Am Heart J., (19570000), vol. 54, doi:doi:10.1016/0002-8703(57)90079-0, pages 59 - 68, XP022944336
DOI: http://dx.doi.org/10.1016/0002-8703(57)90079-0
Type:Non-patent literature
Publication information:   - KANG J; CHEN XL; WANG H et al., "Discovery of a small molecule activator of the human ether-a-go-go - related gene(HERG) cardiac K+ channel", Mol Pharmacol, (20050000), vol. 67, doi:doi:10.1124/mol.104.006577, pages 827 - 836, XP002556830
DOI: http://dx.doi.org/10.1124/mol.104.006577
Type:Non-patent literature
Publication information:   - KATCHMAN AN; KOERNER J; TOSAKA T; WOOSLEY RL; EBERTY SN, "Comparative evaluation of HERG currents and QWT intervals following challenge with suspected torsadogenic and non-torsdogenic drugs", J Pharmacol Exp Ther., (20060000), vol. 316, no. 3, pages 1098 - 1106
Type:Non-patent literature
Publication information:   - LAYTON D; KEY C; SHAKIR SA, "Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future", Pharmacoepidemiol Drug Saf., (20030000), vol. 12, no. 1, pages 31 - 40
Type:Non-patent literature
Publication information:   - MACIEL NR; REIS PG; KATO KC et al., "Reduced cardio-vascular alterations of tarter emetic administered in long-circulating liposomes in rats", Toxicology Letters, (20100000), vol. 199, no. 3, pages 234 - 238
Type:Non-patent literature
Publication information:   - MEHTA RT; HOPFER RL; GUNNER LA; JULIANO RL; LOPEZ-BERESTEIN G, "Formulation, toxicity ,and antifungal activity in vitro of liposomal-encapsulated nystatin as therapeutic agent for systemic candidiasis", Antimicrob Agents Chemother., (19870000), vol. 31, no. 12, pages 1897 - 1900
Type:Non-patent literature
Publication information:   - MOHA OU MAATI H; DUCROQ J; RIVET J; FAIVRE J.F; LE GRANDE M; BOIS P, "Curcumin blocks the recombinant human cardiac KCNQ1/ KCNE1 channels (IKs) stably expressed in HEK 293 cells. Congress de Physiologie,de Pharmacologie et de Therapeutique", Fund. Clin. Pharmacol., (20080409), vol. 22, no. l
Type:Non-patent literature
Publication information:   - SHIMIZU W; ANTZELEVITCH C, "Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long QT syndrome", Circulation, (19970000), vol. 96, pages 2038 - 2047
Type:Non-patent literature
Publication information:   - SHIMIZU W; ANTZELEVITCH C, "Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes LQT1, LQT2, and LQT3 models of the long QT syndrome", Circulation, (20000000), vol. 102, pages 702 - 712
Type:Non-patent literature
Publication information:   - STANSFELD PJ; GEDECK P; GOSLING M; COX B; MITCHESON JS; SUTCLIF MJ, "Drug block of the hERG potassium Channel: insight from modeling", Proteins, (20070000), vol. 68, no. 2, pages 568 - 580
Type:Non-patent literature
Publication information:   - QUAN XQ; BAI R; LIU N; CHEN BD; ZHANG CT, "Increasing gap junction coupling reduces transmural dispersion of repolarization and prevents torsades de points in rabbit LQT3 model", J Cardiovasc Electrophysiol, (20070000), vol. 18, pages 1184 - 1189
Type:Non-patent literature
Publication information:   - ZAVHARIAE U; GIORDANETTO F; LEACH AG, "Side chain flexabilities in the human ether-a-go-go related potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers", J Med Chem, (20090000), vol. 52, no. 14, pages 4266 - 4276
Type:Non-patent literature
Publication information:   - ZHOU Z; GONG Q, "January CT: Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome: Pharmacological and temperature effects", J Biol Chem., (19990000), vol. 274, doi:doi:10.1074/jbc.274.44.31123, pages 31123 - 31126, XP002281088
DOI: http://dx.doi.org/10.1074/jbc.274.44.31123